ORIC Launches Phase 3 Himalayas-1 Trial
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 14, 2026 ORIC Pharmaceuticals announced the initiation of the global Himalayas-1...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 14, 2026 ORIC Pharmaceuticals announced the initiation of the global Himalayas-1...
LEVERKUSEN, Germany, July 10, 2026 Bayer AG has announced a landmark €3.0 billion equity investment agreement with global asset...
BERLIN, Germany, May 19, 2026 Bayer has announced that the U.S. Food and Drug Administration (FDA) and Japan’s Ministry...
ALBANY, N.Y., May 19, 2026 Curia Global, Inc. has announced the completion of a major upgrade to its aseptic...
MINNEAPOLIS, Minn., May 19, 2026 MEKanistic Therapeutics has announced that the U.S. Food and Drug Administration (FDA) cleared the...
BERLIN, Germany, May 18, 2026 Bayer has announced that the U.S. Food and Drug Administration (FDA) granted Priority Review...
BERLIN, Germany / WHIPPANY, N.J., May 7, 2026 Bayer announced positive topline results from the pivotal Phase III REVEAL...
CAMBRIDGE, Mass., May 6, 2026 Nona Biosciences, a global biotechnology company specializing in biotherapeutic discovery and AI-driven drug development...
BERLIN, Germany, and SAN FRANCISCO, Calif., May 6, 2026 Bayer has announced an agreement to fully acquire Perfuse Therapeutics...
